Type 2 diabetes and metabolic disease are now so common that they are treated as an expected part of modern life rather than as a systemic failure. Roughly 90 percent of American adults are now prediabetic or diabetic, and most are unaware of it. This progression quietly opens the door to heart disease, non-alcoholic fatty liver disease, cancer, neurodegeneration, and other chronic illnesses that are then managed downstream.
We are not facing an epidemic of defective biology. We are facing an epidemic of chronically elevated blood sugar. That distinction matters.
Type 2 diabetes is not a mystery
Type 2 diabetes can be described very simply: chronically elevated blood sugar (CEBS). Not insulin deficiency. Not a mysterious resistance syndrome. Not a failure of willpower. Just glucose remaining elevated, chronically.
Blood sugar rises when we eat. That is normal. Blood sugar becomes chronically elevated when we eat in a way that keeps supplying glucose faster than the body can clear or safely store it. And that is no longer rare behavior. It is the dominant pattern.
Insulin is not a dictator; it is a messenger
When blood glucose rises, insulin rises. That is not pathological; it is protective. Insulin’s job is to signal that fuel is available and to invite tissues to take it up so glucose does not remain in the bloodstream at toxic levels.
But insulin does not force glucose into cells. Cells decide whether to accept it.
When cells are already energetically replete, they reduce further glucose uptake. This is not “resistance” in the mechanical sense. It is a regulated, protective response to substrate oversupply. This phenomenon is often called “insulin resistance,” but that term is misleading. It implies failure. It implies pathology at the cellular level. It implies that something is broken.
What is actually happening is substrate prioritization and preservation.
The Randle cycle describes this clearly: Cells preferentially oxidize either fat or glucose depending on availability. When glucose is chronically abundant, cells limit further uptake to avoid intracellular stress and damage.
This is not malfunction. This is self-preservation. Calling it “insulin resistance” shifts attention away from the cause (chronic glucose oversupply) and onto the response (reduced uptake), and then treats the response as the disease. That inversion has consequences.
Treating the signal instead of the source
The dominant medical response to chronically elevated blood sugar is to:
- Increase insulin (endogenous or injected)
- Increase glucose-lowering medications
- Add additional medications as control deteriorates
What we are not doing, institutionally, structurally, or educationally, is addressing why glucose is chronically elevated in the first place.
We are extremely comfortable managing blood sugar pharmacologically. We are far less comfortable questioning dietary substrate load.
This is not because physicians are negligent. It is because nutrition and metabolic physiology are structurally marginalized in medical education, while pharmacologic approaches are structurally privileged, by funding, by curriculum design, and by reimbursement systems.
Physicians are trained to practice within the boundaries of what is reimbursable, regulated, and professionally supported, which means managing symptoms far more often than addressing causes. The structure of modern medicine does not meaningfully support upstream metabolic intervention, even when clinicians recognize its relevance.
Root-cause metabolic treatment sits largely outside that structure. Many clinicians sense this gap, but only those who actively seek out additional training or perspectives are ever exposed to a framework for addressing it.
Carbohydrate load is the dominant driver
There are three macronutrients: protein, fat, and carbohydrate. Humans require protein and fat to survive. We do not require exogenous carbohydrates.
Carbohydrates are uniquely glucose-raising. Eat carbohydrate, blood glucose rises, insulin rises to control it. Do this occasionally, and the system handles it easily. Do this repeatedly, all day, every day, particularly with refined carbohydrates and sugars, and glucose remains elevated chronically.
This is not a random pathology. It is a predictable physiological state: chronically elevated blood sugar (CEBS).
CEBS is not itself a disease in the classic sense. It is a condition of persistent metabolic input, and it is the upstream state from which most modern metabolic disease develops.
Non-alcoholic fatty liver disease provides a clear analogy. When alcohol causes fatty liver disease, the treatment is obvious: Remove the alcohol. When glucose and fructose overload the liver, we label the resulting state a “disease” and treat it pharmacologically, rather than removing the input that created it.
This is not a scientific limitation. It is a cultural and institutional one.
The uncomfortable implication
If chronically elevated blood sugar is driven primarily by chronically elevated carbohydrate intake, then:
- The condition is not spontaneous.
- The primary intervention is not pharmaceutical.
- The dominant model of care is structurally incomplete.
This does not make physicians wrong. It means the system they were trained in is constrained by its own design. This is the “bear” that needs to be gently but clearly poked, not to attack medicine, but to allow it to evolve.
A reframing that restores coherence
When we reframe type 2 diabetes as a state of chronic glucose oversupply, insulin “resistance” as protective regulation of glucose entry, fat storage as energy buffering, and metabolic disease as a systems-level substrate mismatch, the contradictions dissolve.
The body is not failing. It is adapting. And our task becomes not to override that adaptation, but to remove the condition that made it necessary.
Conclusion
“Insulin resistance” is not the disease. It is the body’s attempt to survive the condition.
Chronically elevated blood sugar is not a mysterious pathology. It is a predictable outcome of a food environment and medical model that treat glucose exposure as benign and pharmaceutical suppression as sufficient.
If we want different outcomes, we will need to ask different questions. Not just “How do we lower blood sugar?” but “Why is blood sugar elevated all the time?”
That shift does not diminish medicine. It completes it.
Kevin Whitt is a metabolic health educator.
